リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Inactivation of SARS-CoV-2 by povidone-iodine products: implications for effective mouth rinsing and gargling」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Inactivation of SARS-CoV-2 by povidone-iodine products: implications for effective mouth rinsing and gargling

Kariwa, Hiroaki Sawa, Hirofumi Kobayashi, Shintaro 北海道大学

2021.08

概要

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is transmitted mainly via droplets and contact. The implementation of infection control measures is important to reduce the number of COVID-19 cases. Thus, the ability of several povidone-iodine (PVP-I) products to inactivate SARS-CoV-2 was evaluated based on their in vitro inactivation efficacy. PVP-I solutions such as Isodine Gargle® (ethical and consumer products), Isodine Gargle C® , and Isodine Nodo Fresh® for 30 or 60 s decreased the viral infectivity level from 2-4 × 106 TCID50/ml to below the detectable level (> 99.9% reduction). Our results indicate that the use of Isodine® mouthwash and gargle products is an effective infection control measure against SARS-CoV-2.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1) Anderson DE, Sivalingam V, Kang AEZ, Ananthanarayanan A, Arumugam H, Jenkins TM, Hadjiat Y, Eggers M. Povidone-Iodinedemonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther 9(3), 669- 675, 2020.

2) Barreto R, Barrois B, Lambert J, Malhotra- Kumar S, Santos-Fernandes V, Monstrey S. Addressing the challenges in antisepsis: focus on povidone iodine. Int J Antimicrob Agents 56, 106064, 2020.

3) Benevento WJ, Murray P, Reed CA, Pepose JS. The sensitivity of Neisseria gonorrhoeae, Chlamydia trachomatis, and herpes simplex type II to disinfection with povidone-iodine. Am J Ophthalmol 109, 329-333, 1990.

4) Chopra A, Sivaraman K, Radhakrishnan R, Balakrishnan D, Narayana A. Can povidone iodine gargle/mouthrinse inactivate SARS- CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update. Jpn Dent Sci Rev 57, 39-45, 2021.

5) Chowdhury R, Boorla VS, Maranas CD. Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity. Comput Struct Biotechnol J 18, 2573-2582, 2020.

6) Coronavirid ae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5, 536-544, 2020.

7) Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel) 11, 579. 2021.

8) Hall CB, Geiman JM, Douglas RG Jr, Meagher MP. Control of nosocomial respiratory syncytial viral infections. Pediatrics 62, 728-32, 1978.

9) Indari O, Jakhmola S, Manivannan E, Jha HC. An update on antiviral therapy against SARS-CoV-2: How far have we come? Front Pharmacol 12, 632677, 2021.

10) Coronavirus Resource Center of Johns Hopkins University Medicine. World map. https:// coronavirus. jhu. edu/ map. html. (accessed 30 April 2021) 2021.

11) Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 104, 246-251, 2020.

12) Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone- iodine, physical conditions, and chemical reagents. Jpn J Vet Res. 52 105-112, 2004.

13) Kishimoto M, Uemura K, Sanaki T, Sato A, Hall WW, Kariwa H, Orba Y, Sawa H, Sasaki M. TMPRSS11D and TMPRSS13 activate the SARS-CoV-2 spike protein. Viruses 13, 384, 2021.

14) Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 55, 105924, 2020.

15) Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members. Operation Warp Speed: implications for global vaccine security. Lancet Glob Health S2214- 109X(21) 00140-6. 2021.

16) Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kageyama T, Takeda M. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA 117, 7001-7003. 2020.

17) Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol 79, 104212, 2020.

18) Sattar SA, Raphael RA, Lochnan H, Springthorpe VS. Rotavirus inactivation by chemical disinfectants and antiseptics used in hospitals. Can J Microbiol 29, 1464-1469, 1983.

19) Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 12, 15-22, 2006.

20) Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269, 2020.

21) Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8), 727-733, 2020.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る